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The novel coronavirus SARS-CoV-2, causing the disease 
COVID-19, first emerged in Wuhan, China in December 2019 
and has now spread to 203 countries or territories, infected over 
2 million people and caused over 133,000 deaths. There is an 
urgent need for specific treatments. One potential treatment is 
chloroquine and its derivatives, including hydroxychloroquine, 
which have both antiviral and anti-inflammatory effects. 
These compounds are effective against SARS-CoV-2 in vitro, 
but in vivo data are lacking. Although some encouraging 
outcomes have been reported, and these results have been 
received enthusiastically, we recommend careful and critical 
evaluation of current evidence only when all methods and data 
are available for peer review. Chloroquine is safe and cheap. 
However, further evidence from coordinated multicentre trials is 
required before it can be confidently said whether it is effective 
against the current pandemic.




On 31 December 2019, a cluster of novel coronavirus cases, associated 
with fever, shortness of breath and bilateral lung infiltrates, linked 
to exposure to a seafood market, was reported to the WHO China 
Country Office.1 A previously unidentified betacoronavirus, initially 
named 2019-nCoV, was isolated from broncheoalveolar-lavage 
samples of patients.2 The novel coronavirus has since been named 
SARS-CoV-2 and the disease it causes, COVID-19.3 SARS-CoV-2 is a 
member of the coronavirus family. These are large, enveloped, single-
stranded RNA viruses. There are four endemic strains (HCoV 229E, 
NL63, OC43, HKU1) which infect humans causing mild illnesses such 
as ‘the common cold’.4 Also in this family are severe acute respiratory 
syndrome coronavirus (SARS-CoV) and Middle East respiratory 
syndrome coronavirus (MERS-CoV). Both are highly pathogenic, causing 
respiratory illnesses with high mortality rates: 9.6% in SARS-CoV and 
36.1% in MERS-CoV.5 As of 15 April 2020 there have been 2,069,246 
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Initial evidence from Wuhan, China suggested that the most 
common symptoms at the onset of illness were fever (98%), cough 
(76%) and myalgia/fatigue (44%).7 Older males with existing 
health conditions were more likely to be affected.8 19.6% of 
patients developed acute respiratory distress syndrome (ARDS); 
other complications included shock (8.7%), acute cardiac injury 
(7.2%), arrhythmia (16.7%) and acute kidney injury (3.6%). 
61.1% of patients in the intensive care unit (ITU) had ARDS 
compared to 4.9% of non-ITU patients. The medium time from 
onset of symptoms to development of ARDS was 8 days.9 There 
is a desperate need to develop methods to combat viral spread, 
including vaccine development and treatment options. A variety 
of medications have been suggested, including chloroquine 
phosphate, interferon-alpha and ribavirin.10 There has been 
particular interest surrounding the use of antivirals with anti-
inflammatory properties, as it has been proposed that the 
ARDS seen in COVID-19 patients could be a result of a cytokine 
storm when the immune system attempts to respond to the 
virus.11 Chloroquine and its derivatives, including the less toxic 
hydroxychloroquine, have been used to treat a variety of diseases 
including systemic lupus erythematous, rheumatoid arthritis 
and malaria, among many other indications.12  It has previously 
been studied as a treatment of other coronaviruses, making it a 
potential candidate for treating COVID-19. Chloroquine inhibited 
replication of HCoV-OC43 in vitro. In vivo the survival rate of 
newborns of pregnant mice treated with chloroquine was 100% 
when exposed to the coronavirus, compared to 0% in the offspring 
of untreated pregnant mice.13 Chloroquine phosphate or related 
compounds have also been found to be effective at inhibiting 
SARS-CoV in vitro;14–16 however, it showed no significant efficacy at 
reducing viral titres in the lungs of infected mice in vivo.16 
The field is rapidly evolving, with new information about the 
virus, and about potential treatments, being published every day. 
This review will summarise the current evidence for chloroquine 
and its analogues in the treatment of SARS-CoV-2.
Mechanism of action 
The mechanism of action of chloroquine and its derivatives, both 
as an antiviral and an anti-inflammatory, have not been fully 
elucidated. Certainly, there are numerous ways in which these 
drugs could exert their anti-SARS-CoV-2 effects. Chloroquine and 
hydroxychloroquine act as weak bases which can have several 
intracellular effects, including affecting intracellular trafficking 
and disrupting enzymes. The antiviral mechanisms in general can 
be broken down into two different mechanisms. First, chloroquine 
may inhibit viral entry steps such as pH-dependent endocytosis,17 
as many of the different stages of any viral entry rely on specific pH 
ranges to allow conformational change.18 Second, the altered pH of 
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the cellular environment may disrupt post translational modifications 
of glycoproteins and therefore affect the infectivity of the virus.18  
In vitro evidence investigating chloroquine on SARS-CoV virus 
would appear to support these mechanisms of actions. SARS-CoV 
enters cells via spike glycoprotein, and chloroquine was found 
to inhibit the transduction of cells with SARS-CoV pseudovirions 
(with only the spike glycoprotein on the cell surface). However, 
chloroquine did not inhibit transduction with pseudovirions with 
a pH-independent surface glycoprotein, suggesting that the 
SARS-CoV spike protein required an acidic pH for cell entry.19 
Additionally, chloroquine does not affect the levels of cell surface 
ACE2 (the receptor for spike glycoprotein), suggesting that it does 
not mediate its antiviral effects by downregulating the number of 
available receptors. However, chloroquine was found to increase 
the electrophoretic mobility of ACE2, which infers that chloroquine 
impaired terminal glycosylation of this receptor. Therefore the 
spike protein on the surface of the SARS-CoV virion is not able to 
interact with its receptor as effectively, reducing viral entry into 
the cell.15 Using immunofluorescence, Liu et al found that both 
chloroquine and hydroxychloroquine reduced the transport of 
SARS-CoV-2 virions from early endosomes to endolysosomes, 
likely due to blocking endosome maturation via prevention of 
acidification. This blocked the transport of infective virions to their 
release site from the infected cell.20  
As well as their antiviral effects, these medications have an anti-
inflammatory component, which is utilised in treating a variety 
of immunological conditions. Biochemical studies on the initial 
cohort of COVID-19 patients in Wuhan, China noted that they had 
elevated levels of cytokines, with those requiring ITU admission 
(and therefore suffering from more severe disease) having higher 
levels of cytokines than those that didn’t. This may suggest 
that the increased disease severity is due to the induction of a 
cytokine storm.7 Again, there are likely to be a variety of complex 
and interconnecting effects which chloroquine exerts in order to 
reduce inflammation, but one of these is likely to be a reduction 
in the production of inflammatory cytokines via inhibition of Toll-
like receptor pathways.21 Hence, as well as acting as an antiviral, 
chloroquine or its derivatives could also mitigate some of the 
destructive sequelae of SARS-CoV-2 infection such as the cytokine 
storm, which contributes to the severity of disease.
In vitro evidence
Wang et al carried out a study investigating the antiviral effects 
on SARS-CoV-2 of several drugs, some of which had previously 
been used against SARS or MERS. These included ribavirin, 
penciclovir, nitazonanide, nafamostat, remdesivir and favipiravir as 
well as chloroquine. These compounds were tested against SARS-
CoV-2 in vitro, to assess the cytotoxicity, virus yield and infection 
rates. They found that chloroquine was effective at reducing 
viral yield in cell supernatant and additionally did so when the 
cells were treated 1 hour before infection as well as 2 hours post 
infection.22 Further investigation by this group focused on the 
antiviral effects of hydroxychloroquine, as this is a more widely 
utilised and better tolerated chloroquine derivative. They found 
that hydroxychloroquine was similarly effective at inhibiting viral 
infection both before and after viral entry.20  
Yao et al found that both chloroquine and hydroxychloroquine 
reduced viral replication of SARS-CoV-2 in a dose-dependent 
manner, but the EC
50
 values for hydroxychloroquine were lower 
than those for chloroquine, suggesting that hydroxychloroquine 
was more efficacious. In addition hydroxychloroquine was a more 
potent antiviral than chloroquine when the cells were pre-treated 
with the drug before viral infection.23 
Finally, while much of the current evidence focuses on either 
chloroquine or hydroxychloroquine, a further anti-malarial which 
may prove effective against COVID-19 is mefloquine. Mefloquine 
is a 4-methanolquinolone, compared to chloroquine and 
hydroxychloroquine which are 4-aminoquinolones.24 A recent study 
found that mefloquine demonstrated complete cytopathic effect 
against cells infected with a closely related coronavirus with no 
pathogenicity towards humans.25 
In vivo evidence
While these in vitro experiments appear promising, supporting the 
hypothetical use of hydroxychloroquine and chloroquine in the 
treatment of COVID-19, the real test is whether similar results can 
be replicated not only in vivo but in humans.
Gao et al reported a news briefing describing results of 
multicentre clinical trial in China investigating the use of 
chloroquine in patients diagnosed with COVID-19, although 
the data are as yet unpublished. They reported that in over 100 
patients chloroquine phosphate performed better than the control 
drug in treating COVID-19 through a variety of outcomes including 
improvement in imaging findings, negative virology findings and 
shorter disease course, without any significant adverse effects. 
Chloroquine was therefore recommended to be included in the 
guidelines for COVID-19 management by the National Health 
Commission of the People’s Republic of China.26 In their letter to 
BioScience Trends, the authors refer to the results of this trial as a 
‘breakthrough’ and while the potential outcomes are huge, they 
do not provide the data to support this claim. A study on around 
100 patients, with unpublished methods and data, is not sufficient 
to recommend a treatment to hundreds of thousands of affected 
people. The implications of this study at present should therefore 
be carefully and cautiously considered. A systematic review of 
current evidence for chloroquine and its derivatives in treatment of 
COVID-19 additionally reviewed the above letter and screened trial 
registries for evidence of the data described and did not find any.27 
A further recent study on 30 patients with coronavirus showed 
that a 5-day course of hydroxychloroquine made a significant 
difference to the progression of COVID-19; however, the authors 
note the need for much larger sample sizes to adequately assess 
the utility of the drug as a treatment.28  
A French research group reported early results from their ongoing 
trial of the use of hydroxychloroquine in 26 confirmed COVID-19 
cases to reduce respiratory viral loads. In addition, azithromycin 
was added depending on clinical presentation to prevent bacterial 
superinfection. They did not compare these treatments against 
a placebo; instead, their negative controls were 16 patients who 
were untreated. They found that 70% of the hydroxychloroquine-
treated group had negative SARS-CoV-2 nasopharyngeal 
swabs at day 6 post first dose, compared to 12.5% in the 
control group. Furthermore, 100% of patients treated with 
both azithromycin and hydroxychloroquine were virologicaly 
negative at day 6 compared to 57.1% of those treated with just 
hydroxychloroquine.29 Certainly, these results are encouraging. 
The successful use of hydroxychloroquine and azithromycin have 
been met with hope and excitement, including being lauded as 
potential ‘game-changers’ by United States president Donald 
Trump.30 However, again, while we eagerly await further data and 
ongoing results from these (and other) trials, there is a need to be 
cautious. 
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Safety
Important aspects to focus on when considering (hydroxy)
chloroquine as a treatment for COVID-19 are its side effect profile, 
safety and tolerability. Certainly, we would expect chloroquine 
to be well tolerated in general given that it has been successfully 
used in humans for treating disease since 193417 and can be taken 
long-term (as travellers visiting countries with a risk of malaria take 
chloroquine as prophylaxis31). Chinese researchers announced that 
in multicentre trials chloroquine had demonstrated ‘acceptable 
safety’ – however, the data to support this in these particular 
trials is lacking.26 A recent systematic review on the efficacy and 
safety of chloroquine for COVID-19 concluded that while there are 
sufficient safety data from the long term use of chloroquine and 
its derivatives for a variety of indications, there is an ongoing need 
for further data in the use of chloroquine in COVID-19.27
The frequency of adverse effects for chloroquine and 
hydroxychloroquine is generally low but higher in patients taking 
chloroquine (28%) compared to hydroxychloroquine (15%).32 A 
systematic review found that the most common adverse effects 
were gastrointestinal side effects, cutaneous effects including 
skin rash, and retinopathy.33 An expert consensus of Chinese 
scientists listed several contraindications to the use of chloroquine 
phosphate in COVID-19 such as pregnancy, chronic liver disease, 
chronic kidney disease, chronic heart disease, retinal disease 
and glucose-6-phosphate deficiency.34 As patients with medical 
comorbidities such as cardiovascular disease appear to be more 
at risk of COVID-19,8 such contraindications could limit the use of 
chloroquine as an effective drug in this disease.
The same consensus described the recommended dosing for 
management of COVID-19 to be 500mg twice a day for 10 days. They 
also recommended monitoring electrolytes and myocardial enzymes 
as well as checking ECG before commencing treatment and repeating 
it on the fifth and tenth day of treatment.34 A recent modelling study 
calculated the optimum dosing of hydroxychloroquine sulfate for 
SARS-CoV-2 at 400mg twice daily, followed by a maintenance dose of 
200mg given twice daily for 4 days.23
It must also be noted that there is a risk to patients who are 
already taking these medications for other indications, as demand 
for them has now rapidly increased with the renewed interest in 
them.35 It is important that the current manufacturing chains are 
able to increase the production of these medications to ensure 
supply to patients who are taking them for rheumatological 
diseases. Additionally, any recommendations for one medication 
over the other may require flexibility based on the ease of access 
to medication in different countries; for example chloroquine has 
limited availability in Iran and therefore hydroxychloroquine may 
have to be used instead, or vice versa depending on supplies.36
The future
As of 28 March 2020, there are 22 trials across China 
registered (www.chictr.org.cn/index.aspx) to research the use 
of either chloroquine or hydroxychloroquine in COVID-19: 
ChiCTR2000031174, ChiCTR2000030987, ChiCTR2000030417 
(withdrawn by researchers), ChiCTR2000030054, 
ChiCTR2000030031 (withdrawn by researchers), 
ChiCTR2000029992, ChiCTR2000029988, ChiCTR2000029975, 
ChiCTR2000029939, ChiCTR2000029935, ChiCTR2000029899, 
ChiCTR2000029898, ChiCTR2000029868, ChiCTR2000029837 
(withdrawn by researchers), ChiCTR2000029826 (withdrawn 
by researchers), ChiCTR2000029803, ChiCTR2000029761, 
ChiCTR2000029760 (withdrawn), ChiCTR2000029741, 
ChiCTR2000029609, ChiCTR2000029559, ChiCTR2000029542.
Additionally, as of 28 March 2020 there are at least 21 trials 
registered on clinicaltrials.gov investigating hydroxychloroquine 
and/or chloroquine: NCT04324463, NCT04323631, NCT04323527, 
NCT04322396, NCT04322123, NCT04321993, NCT04321616, 
NCT04321278, NCT04319900, NCT04318444, NCT04318015, 
NCT04316377, NCT04315948, NCT04315896, NCT04308668, 
NCT04307693, NCT04304053, NCT04303507, NCT04303299, 
NCT04286503, NCT04261517.  
Finally, as of 28 March 2020 there are two trials for chloroquine 
and coronavirus registered on the ISRCTN registry (www.isrctn.
com) investigating chloroquine or hydroxychloroquine in COVID-19 
(ISRCTN86534580, ISRCTN83971151).
The apparently successful use of chloroquine and its derivatives 
in treating COVID-19 is therefore obviously encouraging more 
trials. The sheer number of these already registered is impressive; 
however, there is need for trials to be planned and carried out in a 
coordinated manner, allowing larger numbers of patients included 
across multiple centres to ensure the data is of the highest quality 
possible. 
Another avenue to explore (given the above in vitro evidence 
suggesting that chloroquine or its analogues can reduce viral 
infection if applied before exposure to the virus20,22,23) is whether 
these drugs could be used prophylactically to reduce viral spread 
and therefore the extent of the pandemic.37 One application 
of this could be giving these medications to frontline medical 
staff prophylactically to prevent them from getting infected and 
passing it on to other patients within their healthcare setting. 
Conclusion 
In the midst of a global health emergency, chloroquine or its 
analogues could seem like a ‘game changer’ or a breakthrough. 
However, at present, the World Health Organization (WHO) 
does not recommend any particular antiviral medications, citing 
insufficient evidence to recommend any specific treatment.3 
Instead, current management includes the consideration of 
empirical antibiotics or neuraminidase inhibitors, as trials are 
continuing to attempt to find a specific treatment.38
Chloroquine is cheap, widely regarded as safe, has been used 
for decades,27 and early results of in vitro studies are promising; 
therefore further investigation is definitely warranted. However, so 
far there have not been enough translational investigations to say 
whether chloroquine could be an effective treatment in humans 
with COVID-19. The present in vivo data should be appraised 
critically, with full methodology and data available for peer review. 
We can and should continue to be cautiously optimistic and 
appraise evidence as it becomes available, as making bold claims 
about the evidence as it stands is at best irresponsible and at worst 
dangerous. There should be a push for further comprehensive, 
multicentre, global clinical trials to ensure that a drug, whether 
chloroquine or any other potential treatment, is fully assessed for 
efficacy before being hailed as the answer. 
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